search for




 

Case Report
A Case of Transient Myeloproliferative Disorder Associated with Clonal Trisomy 21 in a Chromosomally Normal Newborn
Clin Pediatr Hematol Oncol 2018;25:191-6.
Published online October 31, 2018
© 2018 Korean Society of Pediatric Hematology-Oncology and Korean Society for Pediatric Neuro-Oncology

Jihyun Park, M.D., Yoo Rha Hong, M.D. and Seom Gim Kong, M.D.

Department of Pediatrics, Kosin University College of Medicine, Busan, Korea
Correspondence to: Seom Gim Kong
Department of Pediatrics, Kosin University College of Medicine, 262 Gamcheon-ro, Seo-gu, Busan 49267, Korea
Tel: +82-51-990-6278
Fax: +82-51-990-3065
E-mail: ana313@hanmail.net
ORCID ID: orcid.org/0000-0003-2361-2221
Received August 10, 2018; Revised August 22, 2018; Accepted September 19, 2018.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Transient myeloproliferative disorder (TMD) is similar to congenital leukemia, with leukocytosis, increased peripheral blast cells, and hepatomegaly in the neonatal period. Although TMD occurs only in patients with Down syndrome and trisomy 21 mosaicism, there have been reports of congenital leukemia with trisomy 21 limited to hematopoietic cells showing spontaneous resolution. We identified trisomy 21 in the leukemic cells in a patient with congenital leukemia. As there was no other gene abnormality, we stopped chemotherapy, and the disease resolved spontaneously. We reviewed the cases of clonal trisomy 21 TMD and found that their clinical features were similar to those of TDM associated with Down syndrome. In conclusion, in a phenotypically normal patient with suspected congenital leukemia, it is necessary to confirm the presence of 21 trisomy. If the neonate has only trisomy 21 without other gene abnormalities, intensive chemotherapy may not be required.
Keywords: Myeloproliferative disorder, Infant, Newborn, Chromosome 21, GATA1 transcription factor
References
  1. Schunk GJ, Lehman WL. Mongolism and congenital leukemia. J Am Med Assoc 1954;155:250-1.
    CrossRef
  2. Klusmann JH, Creutzig U, Zimmermann M, et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood 2008;111:2991-8.
    Pubmed KoreaMed CrossRef
  3. Gamis AS, Alonzo TA, Gerbing RB, et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children’s Oncology Group Study A2971. Blood 2011;118:6752-9.
    Pubmed KoreaMed CrossRef
  4. Homans AC, Verissimo AM, Vlacha V. Transient abnormal myelopoiesis of infancy associated with trisomy 21. Am J Pediatr Hematol Oncol 1993;15:392-9.
    Pubmed
  5. Sandoval C, Pine SR, Guo Q, et al. Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature. Pediatr Blood Cancer 2005;44:85-91.
    Pubmed CrossRef
  6. Weinberg AG, Schiller G, Windmiller J. Neonatal leukemoid reaction. An isolated manifestation of mosaic trisomy 21. Am J Dis Child 1982;136:310-1.
    Pubmed CrossRef
  7. Seibel NL, Sommer A, Miser J. Transient neonatal leukemoid reactions in mosaic trisomy 21. J Pediatr 1984;104:251-4.
    CrossRef
  8. Hanna MD, Melvin SL, Dow LW, Williams D, Dahl G, Mirro J. Transient myeloproliferative syndrome in a phenotypically normal infant. Am J Pediatr Hematol Oncol 1985;7:79-81.
    Pubmed
  9. Jones GR, Weaver M, Laug WE. Transient blastemia in phenotypically normal newborns. Am J Pediatr Hematol Oncol 1987;9:153-7.
    Pubmed CrossRef
  10. Kalousek DK, Chan KW. Transient myeloproliferative disorder in chromosomally normal newborn infant. Med Pediatr Oncol 1987;15:38-41.
    CrossRef
  11. Abe K, Kajii T, Niikawa N. Disomic homozygosity in 21-trisomic cells : a mechanism responsible for transient myeloproliferative syndrome. Hum Genet 1989;82:313-6.
    Pubmed CrossRef
  12. Faed MJ, Robertson J, Todd AS, Sivakumaran M, TarnowMordi WO. Trisomy 21 in transient myeloproliferative disorder. Cancer Genet Cytogenet 1990;48:259-64.
    CrossRef
  13. Ridgway D, Benda GI, Magenis E, et al. Transient myeloproliferative disorder of the Down type in the normal newborn. Am J Dis Child 1990;144:1117-9.
    CrossRef
  14. Brissette MD, Duval-Arnould BJ, Gordon BG, Cotelingam JD. Acute megakaryoblastic leukemia following transient myeloproliferative disorder in a patient without Down syndrome. Am J Hematol 1994;47:316-9.
    Pubmed CrossRef
  15. Richards M, Welch J, Watmore A, Readett D, Vora AJ. Trisomy 21 associated transient neonatal myeloproliferation in the absence of Down’s syndrome. Arch Dis Child Fetal Neonatal Ed 1998;79:F215-7.
    Pubmed KoreaMed CrossRef
  16. Carpenter E, Valverde-Garduno V, Sternberg A, et al. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder. Br J Haematol 2005;128:548-51.
    Pubmed CrossRef
  17. Kempski HM, Craze JL, Chessells JM, Reeves BR. Cryptic deletions and inversions of chromosome 21 in a phenotypically normal infant with transient abnormal myelopoiesis: a molecular cytogenetic study. Br J Haematol 1998;103:473-9.
    Pubmed CrossRef
  18. Worth LL, Zipursky A, Christensen H, Tubergen D. Transient leukemia with extreme basophilia in a phenotypically normal infant with blast cells containing a pseudodiploid clone, 46,XY i(21)(q10). J Pediatr Hematol Oncol 1999;21:63-6.
    Pubmed CrossRef
  19. Polski JM, Galambos C, Gale GB, Dunphy CH, Evans HL, Batanian JR. Acute megakaryoblastic leukemia after transient myeloproliferative disorder with clonal karyotype evolution in a phenotypically normal neonate. J Pediatr Hematol Oncol 2002;24:50-4.
    Pubmed CrossRef
  20. Slayton WB, Spangrude GJ, Chen Z, Greene WF, Virshup D. Lineage-specific trisomy 21 in a neonate with resolving transient myeloproliferative syndrome. J Pediatr Hematol Oncol 2002;24:224-6.
    Pubmed CrossRef
  21. Wolfe LC, Weinstein HJ, Ferry JA. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 19-2003. A five-day-old girl with leukocytosis and a worsening rash from birth. N Engl J Med 2003;348:2557-66.
    Pubmed CrossRef
  22. Magalhães IQ, Splendore A, Emerenciano M, et al. Transient neonatal myeloproliferative disorder without Down syndrome and detection of GATA1 mutation. J Pediatr Hematol Oncol 2005;27:50-2.
    CrossRef
  23. Cushing T, Clericuzio CL, Wilson CS, et al. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder. J Pediatr 2006;148:687-9.
    Pubmed CrossRef
  24. Adam M, Vincenot A, Gouraud F, et al. Transient myeloproliferative disorder in a neonate without Down syndrome. Ann Biol Clin (Paris) 2007;65:569-73.
  25. Li-Thiao-Te V, Bourges-Petit E, Capiod JC, et al. Congenital transient leukemia: a case report. Arch Pediatr 2008;15:33-6.
    Pubmed CrossRef
  26. Apollonsky N, Shende A, Ouansafi I, Brody J, Atlas M, Aygun B. Transient myeloproliferative disorder in neonates with and without Down syndrome: a tale of 2 syndromes. J Pediatr Hematol Oncol 2008;30:860-4.
    Pubmed CrossRef
  27. Yanase K, Kato K, Katayama N, et al. Transient abnormal myelopoiesis in a cytogenetically normal neonate. Int J Hematol 2010;92:527-30.
    Pubmed CrossRef
  28. Tsai MH, Hou JW, Yang CP, et al. Transient myeloproliferative disorder and GATA1 mutation in neonates with and without Down syndrome. Indian J Pediatr 2011;78:826-32.
    Pubmed CrossRef
  29. Inaba H, Londero M, Maurer SH, et al. Acute megakaryoblastic leukemia without GATA1 mutation after transient myeloproliferative disorder in an infant without Down syndrome. J Clin Oncol 2011;29:e230-3.
    Pubmed KoreaMed CrossRef
  30. Ohkawa T, Miyamoto S, Sugie M, et al. Transient abnormal myelopoiesis in non-Down syndrome neonate. Pediatr Int 2015;57:e14-7.
    Pubmed CrossRef
  31. Carruthers V, Nicola M, Venugopal P, Hahn CN, Scott HS, Revesz T. Clinical implications of transient myeloproliferative disorder in a neonate without Down syndrome features. J Paediatr Child Health 2017;53:1018-20.
    Pubmed CrossRef
  32. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002;32:148-52.
    Pubmed CrossRef
  33. Al-Kasim F, Doyle JJ, Massey GV, Weinstein HJ, Zipursky A;Pediatric Oncology Group. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome:Pediatric Oncology Group study. J Pediatr Hematol Oncol 2002;24:9-13.
    Pubmed CrossRef


October 2018, 25 (2)
Full Text PDF
Citation
Send to a friend
Twitter
Facebook

Cited By Articles
  • CrossRef (0)

Author ORCID Information
  • Seom Gim Kong